comprehensive -WSS

comprehensive

author：knowledge 2025-09-29 13:31:16 - browse：2

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Death of patient in Alzheimer’s trial raises question of possible risks

WSS

Europe sees delivery challenges ahead on Alzheimer's therapies

Care demand spikes challenge UnitedHealth’s provider arm

Georgia court denies Trump's request to quash DA's 2020 election probe

Who gets to use the title 'doctor'?

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

Everything to know for the next Powerball drawing as jackpot hits $1 billion

hotspot

comprehensive

hotspot

Drug repurposing or repositioning? The language matters

Blood tests recalled over risk of missed heart attack diagnosis

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

The science behind Janet Jackson's pregnancy at 49

The high cost of giving birth even with insurance

RFK Jr. accused of antisemitic claims about COVID but insists he was misunderstood

The cancer drug shortage isn’t new — and neither are the solutions

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Medical records are filled with copy

Congress: Eradicate hepatitis C and reduce the deficit

hotspot

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

Gene therapy has helped boys walk. Can scientists keep it that way?

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

Manchin, Huntsman team up to talk platform for 'unity' ticket that could run in 2024

3 hurdles to bringing medical devices to the U.S. market

focus

focus

focus

explore